STAGE IVA LIP AND ORAL CAVITY CANCER AJCC V8
Clinical trials for STAGE IVA LIP AND ORAL CAVITY CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IVA LIP AND ORAL CAVITY CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IVA LIP AND ORAL CAVITY CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy aims to boost survival in head and neck cancer
Disease control Recruiting nowThis phase II trial tests whether adding chemotherapy or chemo-immunotherapy before standard salvage surgery helps patients with recurrent or persistent head and neck cancer. About 180 participants with PD-L1 positive tumors will receive either carboplatin and paclitaxel, or thos…
Matched conditions: STAGE IVA LIP AND ORAL CAVITY CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 23, 2026 20:01 UTC
-
New drug combo aims to boost chemoradiation for head and neck cancer
Disease control Recruiting nowThis early-phase study tests whether adding the experimental drug ipatasertib to standard chemotherapy and radiation is safe and effective for people with advanced head and neck cancer. Ipatasertib may help stop cancer cell growth. About 46 participants will receive the combinati…
Matched conditions: STAGE IVA LIP AND ORAL CAVITY CANCER AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 18, 2026 11:50 UTC
-
Can a gene test guide better treatment for head and neck cancer survivors?
Disease control Recruiting nowThis study compares two treatments after surgery for stage III-IVA head and neck cancer: radiation alone versus radiation plus the chemotherapy drug cisplatin. The goal is to see which approach better prevents the cancer from returning, especially in patients with certain TP53 ge…
Matched conditions: STAGE IVA LIP AND ORAL CAVITY CANCER AJCC V8
Phase: PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jun 17, 2026 12:08 UTC
-
Could a Two-Drug punch before surgery shrink head & neck tumors?
Disease control Recruiting nowThis study tests whether adding an experimental drug (CDX-1140) to a standard immunotherapy (cemiplimab) before surgery can shrink advanced head and neck cancers more than the immunotherapy alone. About 44 people with stage III-IV head and neck cancer will receive either the comb…
Matched conditions: STAGE IVA LIP AND ORAL CAVITY CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 12, 2026 12:08 UTC
-
New drug plus precision radiation aims to tame recurrent head and neck cancer
Disease control Recruiting nowThis early-stage trial tests a drug called camonsertib combined with precise radiation for head and neck cancer that has returned or cannot be surgically removed. The study aims to find the safest dose and see if the combination can control tumor growth. About 39 adults with cert…
Matched conditions: STAGE IVA LIP AND ORAL CAVITY CANCER AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 12, 2026 12:07 UTC
-
New drug aims to prevent painful mouth sores in head and neck cancer treatment
Symptom relief Recruiting nowThis study tests whether adding BMX-001 to standard care can reduce severe mouth sores caused by chemoradiation in head and neck cancer patients. About 98 participants will receive either BMX-001 or a placebo alongside usual mouth rinses and pain medications. The goal is to impro…
Matched conditions: STAGE IVA LIP AND ORAL CAVITY CANCER AJCC V8
Phase: PHASE2 • Sponsor: NRG Oncology • Aim: Symptom relief
Last updated Jun 15, 2026 18:57 UTC